GMA
Wooree Green Science announced the US introduction of LipoPrime™, a liposomal ingredient platform positioned around analytical measures of encapsulation, stability and performance.
The important issue is not the word “liposomal” itself. Particle size and distribution, active loading, shelf-life integrity, dosage-form compatibility and behaviour in the matrix are what make systems comparable.
For product developers, the launch suggests a more demanding due-diligence checklist. Greater-bioavailability claims should be tied to data on the specific ingredient and, where relevant, a clinical comparison with a conventional form.
In B2B nutraceuticals, delivery-system differentiation will increasingly depend on methods, specifications and comparable data rather than technology names.
A commercial launch. Full data, transfer across actives and any clinical advantage must be evaluated product by product.
Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.
Read the original source · Wooree Green Science / Yahoo Finance ↗